Cheng Yuanyuan, Gong Shushu, Li Qianqian, Shen Juan, Huang Hongjuan
Department of Radiology, The Haimen Hospital Affiliated of Nantong University, Nantong 226100, Jiangsu Province, China.
Department of Oncology, The Haimen Hospital Affiliated of Nantong University, Nantong 226100, Jiangsu Province, China.
J Cancer. 2024 Sep 3;15(17):5594-5604. doi: 10.7150/jca.97637. eCollection 2024.
To demonstrate the efficacy of photodynamic therapy (PDT) using hematoporphyrin derivative (HPD) nanomedicine in combination with conventional chemotherapy based on gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) magnetic resonance imaging (MRI) for hepatocellular carcinoma (HCC) therapy. HPD nanomedicine was prepared, and the cytotoxicity of HPD nanomedicine at different concentrations on HCC cells and the half-maximal inhibitory concentration (IC) were analyzed. Sixty HCC patients who visited our hospital from 2021 to 2023 were retrospectively analyzed. Patient data were analyzed, with 30 cases in control group (CG) receiving conventional chemotherapy for HCC, and 30 cases in observation group (OG) receiving conventional chemotherapy combined with HPD nanomedicine PDT. Gd-DTPA MRI was utilized to monitor the morphological and biological characteristics of the lesions in patients. After treatment completion, the long-term efficacy of patients and the levels of bcl-2 and bax proteins in primary HCC cells were evaluated. The IC values of HPD on HepG2 cell proliferation and the cell inhibition rates gradually increased with increasing doses of HPD (50 μM, 25 μM, 12.5 μM, 6.25 μM, 3.13 μM, 1.56 μM, 0.78 μM). HPD exhibited great anti-proliferative effects on HepG2 cells at relatively low concentrations. The differences in expression rates of bcl-2 protein and bax protein between groups were considerable (<0.05). There were neglectable changes in AST and ALT levels between the two groups before treatment, but they were markedly reduced after treatment versus before treatment (<0.05), with OG showing considerably lower levels than CG after treatment (<0.05). Additionally, patients in OG exhibited better survival rates after the course of treatment versus those in CG. This study demonstrates that the combination of conventional chemotherapy based on Gd-DTPA MRI with HPD nanomedicine PDT greatly improves the efficacy of treatment for HCC patients. This combined treatment strategy not only enhances therapeutic outcomes but also alleviates adverse reactions associated with conventional treatment, providing a novel approach for future research in the treatment of HCC.
为了证明使用血卟啉衍生物（HPD）纳米药物的光动力疗法（PDT）联合基于钆-二乙烯三胺五乙酸（Gd-DTPA）磁共振成像（MRI）的传统化疗对肝细胞癌（HCC）的治疗效果。制备了HPD纳米药物，并分析了不同浓度的HPD纳米药物对肝癌细胞的细胞毒性和半数抑制浓度（IC）。回顾性分析了2021年至2023年到我院就诊的60例HCC患者。分析患者数据，对照组（CG）30例接受HCC的传统化疗，观察组（OG）30例接受传统化疗联合HPD纳米药物PDT。利用Gd-DTPA MRI监测患者病变的形态和生物学特征。治疗结束后，评估患者的长期疗效以及原发性肝癌细胞中bcl-2和bax蛋白的水平。HPD对HepG2细胞增殖的IC值和细胞抑制率随HPD剂量（50μM、25μM、12.5μM、6.25μM、3.13μM、1.56μM、0.78μM）增加而逐渐升高。HPD在相对较低浓度下对HepG2细胞表现出强大的抗增殖作用。两组之间bcl-2蛋白和bax蛋白表达率差异显著（<0.05）。两组治疗前AST和ALT水平变化可忽略不计，但治疗后与治疗前相比显著降低（<0.05），治疗后OG组水平显著低于CG组（<0.05）。此外，与CG组相比，OG组患者在疗程结束后的生存率更高。本研究表明，基于Gd-DTPA MRI的传统化疗与HPD纳米药物PDT联合应用可显著提高HCC患者的治疗效果。这种联合治疗策略不仅提高了治疗效果，还减轻了传统治疗相关的不良反应，为未来HCC治疗研究提供了一种新方法。
